Thursday, 23 Jan 2020

You are here

Sprifermin Benefits Cartilage Loss but not Symptoms in Knee Osteoarthritis

Intra-articular sprifermin given to patients with symptomatic and radiographic knee osteoarthritis has been shown to significantly improve total femorotibial joint cartilage thickness after 2 years, but without significant clinical beneftis. Which begs the question, why is there a disconnect between radiographic disease modification (cartilage thickness) and symptomatic improvement?

Sprifermin, recombinant human fibroblast growth factor 18 (rhFGF18) (insulin-like growth factor 1 bone morphogenetic protein 7), is being developed as a potential anabolic disease-modifying agent for osteoarthritis (DMOAD).

The FORWARD trial enrolled 549 participants who were randomized to 30 μg or 100 μg of sprifermin every 6 or 12 months vs placebo.

Spifermin was given four ways - 100 μg of sprifermin every 6 months (n = 110) or every 12 months (n = 110), or 30 μg of sprifermin every 6 months (n = 111) or every 12 months (n = 110), and placebo every 6 months (n = 108). Each treatment consisted of weekly injections over 3 weeks. The primary end point was change in total femorotibial joint cartilage thickness measured by quantitative magnetic resonance imaging at 2 years.

At 2 years, 86.3% completed the 2-year follow-up. Compared with placebo, the changes from baseline to 2 years in total femorotibial joint cartilage thickness was:

  • 100 μg every 6 months - 0.05 mm (95% CI, 0.03 to 0.07 mm)
  • 100 μg every 12 months - 0.04 mm (95% CI, 0.02 to 0.06 mm)
  • 30 μg every 6 months - 0.02 mm (95% CI, −0.01 to 0.04 mm)
  • 30 μg every 12 months 0.01 mm (95% CI, −0.01 to 0.03 mm)

Clinically, there were no statistically significant changes from total WOMAC scores when comparing sprifermin vs. PBO.

It is unclear what benefit may ensue from MRI improvements without clinical benefits.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Should We Screen Younger Postmenopausal Women for Osteoporosis?

Do postmenopausal women, under age 65 years, need a baseline BMD testing? A JAMA Insights review suggests that the absolute risk of fracture is low in this group and that USPSTF guidelines should be considered - that we should be screening women younger than 65 years who are at increased risk of osteoporosis and we should be using a formal risk assessment tool to identify candidates for bone density testing.

Genicular Artery Embolization to Treat Osteoarthritis Knee Pain

A study from the Journal of Vascular and Interventional Radiology has shown that  knee pain secondary to osteoarthritis (OA) may be effectively treated by selective vascular interruption (embolization) showing efficacy and safety in a small pilot trial. 

ACR-Arthritis Foundation Treatment Guidelines for Osteoarthritis

Today, the American College of Rheumatology (ACR), in partnership with the Arthritis Foundation (AF), released the 2019 ACR/AF Guideline for the Management of Osteoarthritis of the Hand, Hip and Knee. The ACR periodically updates guidelines to reflect any advances in management added to the literature since the last publication, which in this case was 2012.

Short-term Benefit with Prednisolone in Hand Osteoarthritis

Lancet reports that prednisolone 10 mg daily for 6 weeks can effectively control the pain of hand osteoarthritis (OA), according to results from the Hand Osteoarthritis Prednisolone Efficacy (HOPE) study. This was a double-blind, randomized, placebo-controlled trial aimed to assess the short-term effects of prednisolone in painful hand OA and synovial inflammation. Patients were required to have hand OA and signs of inflammation in their distal and proximal interphalangeal (DIP/PIP) joints and > 4 DIP/PIP osteoarthritic nodes and at least one DIP/PIP joint with soft swelling/erythema or evidence of synovitis on power Doppler ultrasound. The primary endpoint was finger pain.

Physical Activity Lowers Fracture Risk in Post-Menopausal Women

An analysis from the Women’s Health Initiative study shows that postmenopausal women who participate in vigorous physical activity have a statistically lower risk of total and site-specific fractures